Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis

Massimo Franchini[1,2], Carlo Mengoli[1], Mario Cruciani[3], Valentino Bergamini[4], Francesca Presti[4], Giuseppe Marano[1], Simonetta Pupella[1], Stefania Vaglio[1,5], Francesca Masiello[1], Eva Veropalumbo[1], Vanessa Piccinini[1], Ilaria Pati[1], Giancarlo M. Liumbruno[1]

[1]Italian National Blood Centre, National Institute of Health, Rome; [2]Department of Haematology and Transfusion Medicine, "Carlo Poma" Hospital, Mantua; [3]Infection Control Committee, AULSS9 "Scaligera", Verona; [4]Department of Obstetrics and Gynecology, "Azienda Ospedaliera Universitaria Integrata", Verona; [5]Department of Clinical and Molecular Medicine, "La Sapienza" University of Rome, Rome, Italy

Background. A number of clinical systematic review and meta-analysis have been published on the use of tranexamic in the obstetric setting. The aim of this meta-analysis was to evaluate the safety and effectiveness of tranexamic acid in reducing blood loss when given prior to caesarean delivery.

Materials and methods. We searched the Cochrane Wounds Specialized Register, Cochrane Central, MEDLINE (through PUBMED), Embase, and SCOPUS electronic databases. We also searched clinical trials registries for ongoing and unpublished studies, and checked reference lists to identify additional studies. We used no restrictions with respect to language and date of publication. Two review authors independently performed study selection, "Risk of bias" assessment, and data extraction. Initial disagreements were resolved by discussion, or by including a third review author when necessary.

Results. We found 18 randomised controlled trials (RCTs) that met our inclusion criteria. Overall, 1,764 women receiving intravenous tranexamic acid for prevention of bleeding following caesarean sections and 1,793 controls receiving placebo were enrolled in the 18 RCTs evaluated. The use of tranexamic acid compared to controls (placebo or no intervention) reduces post-partum haemorrhage >400 mL (risk ratio [RR] 0.40, 95% confidence interval [CI] 0.24-0.65; 5 trials with a total of 786 participants), severe post-partum haemorrhage >1,000 mL (RR 0.32, 95% CI: 0.12-0.84; 5 trials with a total of 1,850 participants), and need for red blood cell transfusion (RR 0.30, 95% CI: 0.18-0.49; 10 trials with a total of 1,873 participants). No particular safety concerns on the use of this antifibrinolytic agent emerged from the analysis of the 18 RCTs included.

Discussion. Overall, the results of this meta-analysis support the evidence of a beneficial effect of tranexamic acid in reducing blood loss and need for blood transfusion in pregnant women undergoing caesarean section.

Keywords: obstetric haemorrhage, post-partum haemorrhage, tranexamic acid, bleeding, prevention.

Introduction

Obstetric haemorrhage is a leading cause of premature maternal mortality, accounting for at least 100,000 deaths each year worldwide[1-4]. Although post-partum haemorrhage (PPH) may be unpredictable, the most common causes include uterine atony, abnormal placentation, retained placental tissue, and lacerations of the lower genital tract[5]. In addition, obesity, multiple pregnancies, and previous caesarean section have been recognised as risk factors for PPH[6]. Considering the health and social burden of PPH, it is not surprising that a number of recommendations and guidelines have been issued from national and international scientific societies and health authorities to optimise the use of obstetric interventions and uterotonic drugs in this critical clinical setting[7-9].

As far as the pathophysiology is concerned, recent evidence has linked the activation of the fibrinolytic pathway with the onset of severe haemorrhage in different settings, including trauma, heart and orthopaedic surgery, and obstetrics[10,11]. Following these observations, several randomised controlled trials (RCTs) have assessed the impact of tranexamic acid (TA), a lysine analogue that inhibits plasmin-mediated fibrin degradation[12], on decreasing bleeding complications and mortality in such clinical conditions at increased haemorrhagic risk[13-21]. The aim of this paper is to provide an up-dated review, through a systematic analysis of the existing literature

on the published RCTs on the safety and efficacy of TA for prevention of postpartum blood loss.

Material and methods

This systematic review was conducted according to the recommended Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist guidelines[22].

Search strategy

A computer-assisted literature search of the MEDLINE (through PUBMED), EMBASE, SCOPUS, OVID and Cochrane Library electronic databases was performed to identify RCTs on the use of TA for prevention and treatment of PPH. A combination of the following text words was used to maximise search specificity and sensitivity: "tranexamic acid" AND "TXA" AND "antifibrinolytic agent" AND "post-partum haemorrhage" AND "PPH" AND "obstetric haemorrhage" AND "caesarean" AND "vaginal" AND "randomized" AND "prevention" AND "treatment". In addition, we checked the reference lists of the most relevant items (original studies and reviews) in order to identify potentially eligible studies not captured by the initial literature search. Abstracts from relevant conferences or scientific meetings were hand-searched for additional studies.

Study selection and inclusion criteria

Study selection was performed independently by two reviewers (MF and MC), with disagreements resolved through discussion and on the basis of the opinion of a third reviewer (CM). Eligibility assessment was based on the title or abstract and on the full text if required. Articles were eligible if they reported either in the title or in the abstract the use of TA for the prevention of PPH. Only RCTs published in full in English between January 1970 and December 2017 were included in this systematic review and meta-analysis. As we found only two RCTs evaluating the efficacy of TA for the prevention of PPH after vaginal delivery[23,24], the present analysis was limited to RCTs evaluating this antifibrinolytic agent after caesarean delivery.

Data extraction and outcome analysis

For each study included in the systematic review, the following data were extracted by two reviewers (MF and MC) independently: publication date, sample size (TA and control groups), and protocol (TA dose administered). The primary outcome was the incidence of PPH (i.e. blood loss more than 400 mL) and severe PPH (i.e. blood loss >1,000 mL). Secondary outcomes included mean blood loss volume (mL), need for blood

transfusion, and overall severe side effects related to TA (including thromboembolic events). Disagreement was resolved by consensus and by the opinion of a third reviewer, if necessary.

Assessment of risk of bias in included studies

Two review authors (MF and MC) independently assessed the risk of bias of each included study following the domain-based evaluation described in the Cochrane Handbook for Systematic Reviews of Interventions[25]. They discussed any discrepancies and achieved consensus on the final assessment. The Cochrane "Risk of bias" tool addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting, and other issues relating to bias. We have presented our assessment of risk of bias using two "Risk of bias" summary figures: 1) a summary of bias for each item across all studies; and 2) a cross tabulation of each trial by all of the "Risk of bias" items.

"Summary of findings" tables

We used the principles of the GRADE system to assess the quality of the body of evidence associated with specific outcomes, and constructed a "Summary of findings" table using REVMAN 5[26]. These tables present key information concerning the certainty of the evidence, the magnitude of the effects of the interventions examined, and the sum of available data for the main outcomes[27]. The "Summary of findings" tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE approach, which defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest (see Online Supplementary Content, Table SI). The certainty of a body of evidence involves consideration of within-trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias[28].

We have presented the following outcomes in the "Summary of findings" table: i) PPH; ii) severe PPH; iii) need for blood transfusion (Table SI).

When evaluating the "Risk of bias" domain, we down-graded the GRADE assessment only when we classified a study as being at high risk of bias for one or more of the following domains: selection, attrition, reporting, and other bias; or when the "Risk of bias" assessment for selection bias was unclear (this was classified as unclear for either the generation of the randomisation sequence or the allocation concealment domain). For the outcomes PPH, need for blood transfusion, and post-partum blood loss, we did not down-grade for high risk of bias in performance and detection domains since we judged that the outcomes

Figure 1 - Flow chart of study inclusion criteria.

considered are not likely to be influenced by lack of blinding, and for unclear "Risk of bias" assessments in other domains.

Data analysis

All calculations were made using Stata 15.1, R v.3.4.3, and REVMAN 5. The effect size measures were the risk ratio (RR) and the risk difference (RD) between the treated arm and the control study arm. The study weight was calculated using the Mantel-Haenszel method. The heterogeneity χ^2 was calculated as the I^2 for the variation due to heterogeneity[25]. If significant heterogeneity was detected, a random effect method of study weight calculation was followed (DerSimonian-Laird method)[29]; otherwise, the fixed effect procedure was used. We also calculated the number needed to treat (NNT), which is the average number of patients who need to be treated in order to avoid (or to harm) an event.

Results

Literature search and study characteristics

In total, 4,567 articles were initially identified after the initial electronic and manual search, which was concluded on 7 January 2018 (Figure 1). Of them,

4,502 were excluded because they were focusing on other topics. Thus, 65 potentially relevant articles were selected and the next screening led to the exclusion of 47 additional studies (reviews, protocols of RCTs, not RCTs, studies containing no informative data). The remaining 18 randomised studies[30-47] were finally included in the systematic review and meta-analysis (see Table I for main characteristics and results of the included studies). Overall, 1,764 women receiving intravenous TA for prevention of bleeding following caesarean sections and 1,793 controls receiving placebo were enrolled in the 18 RCTs that went forward for evaluation.

Risk of bias in included studies

Eleven studies were at high risk of bias for one or more domains, and 12 studies were at unclear risk of bias for one or more domains (Figure 2 A and B).

Allocation

We assessed two studies as being at high risk of selection bias, as randomisation was by alternation of the two treatments, so the intervention allocations could have been foreseen in advance[31,40]. The reports of six

Table I - Characteristics and main results of the 18 randomised controlled trials on the use of tranexamic acid for the prevention of obstetric haemorrhage.

First Author, year[ref.]	Cases (IVTA/C)	Age, years[1]	IVTA dose	Controls	Post-partum blood loss, mL[1]	PPH onset	RBC transfusion	TA-related SAEs
Gai, 2004[25]	91/89	IVTA: 29.71 (4.18) C: 29.75 (4.01)	1 g 10 min before CS	No treatment	IVTA: 359.29 (152.02)[2] C: 439.36 (191.48)[2]	IVTA: 22/91[3] C: 35/89[3]	NR	IVTA: 0/91 C: 0/89
Sekhavat, 2009[26]	45/45	IVTA: 26.2 (4.7) C: 27.1 (4.1)	1 g 10 min before CS	5% glucose	IVTA: 28.02 (5.53)[4] C: 37.12 (8.97)[4]	NR	NR	IVTA: 0/45 C: 0/45
Gungorduk, 2011[27]	330/330	IVTA: 26.3 (3.5) C: 26.6 (3.6)	1 g 10 min before CS	5% glucose	IVTA: 499.9 (206.4)[5] C: 600.7 (215.7)[5]	IVTA: 7/330[6] C: 19/330[6]	IVTA: 2/330 C: 7/330	IVTA: 0/330 C: 0/330
Movafegh, 2011[28]	50/50	IVTA: 27.0 (3.4) C: 27.6 (4.1)	10 mg/kg 20 min before SA	Normal saline	IVTA: 262.5 (39.6)[2] C: 404.7 (94.4)[2]	NR	NR	IVTA: 0/50 C: 0/50
Xu, 2013[29]	88/86	IVTA: 26.7 (3.7) C: 27.1 (4.1)	10 mg/kg 20 min before SA	Normal saline	IVTA: 379.2 (160.1)[2] C: 441.7 (189.5)[2]	IVTA: 19/88[7] C: 28/86[7]	IVTA: 8/88 C: 19/86	IVTA: 2/88 C: 2/86
Shahid, 2013[30]	38/36	IVTA: 24.18 (3.93) C: 24.89 (4.16)	1 g 10 min before CS	Normal saline	IVTA: 356.44 (143.2)[2] C: 710.22 (216.72)[2]	NR	IVTA: 3/38 C: 12/36	IVTA: 0/38 C: 0/36
Goswami, 2013[31]	60/30	IVTA: 23.6 (2.5) C: 24.3 (2.6)	10 or 15 mg/kg 20 min before skin incision	5% glucose	IVTA: 261.17 (56.78) –376.83 (31.96)[8] C: 527.17 (88.67)[8]	IVTA: 0/60[6] C: 0/30[6]	IVTA: 0/60 C: 2/30	IVTA: 0/60 C: 0/30
Senturk, 2013[32]	101/122	IVTA: 30.2 (6.83) C: 29.22 (6.93)	1 g 10 min before CS	5% glucose	IVTA: 272.05 (143.23) C: 346.87 (189.49)	NR	IVTA: 0/101 C: 0/122	IVTA: 0/101 C: 0/122
Abdel-Aleem, 2013[33]	373/367	IVTA: 26.34 (5.16) C: 26.62 (5.05)	1 g 10 min before CS	No treatment	IVTA: 241.61 (126.02)[2] C: 510.66 (144.52)[2]	IVTA: 2/373[6] C: 2/367[6]	NR	IVTA: 0/373 C: 0/367
Ghosh, 2014[34]	70/70	IVTA: 25.94 (3.78) C: 26.04 (3.39)	1 g 10 min before CS	Normal saline	IVTA: 48.06 (8.20)[4] C: 76.01 (6.21)[4]	NR	IVTA: 0/70 C: 3/70	IVTA: 0/70 C: 0/70
Singh, 2014[35]	100/100	IVTA: 25 (1.46) C: 30 (1.24)	1 g 20 min before CS	No treatment	IVTA: 270.05 (30.88)[9] C: 510.45 (30.34)[9]	NR	NR	IVTA: 0/100 C: 0/100
Yehia, 2014[36]	106/106	IVTA: 28.4 (4.9) C: 28.6 (4.7)	1 g 20 min before CS	Normal saline	IVTA: 369.5 (198.0)[9] C: 606.8 (193.0)[9]	IVTA: 33/106[3] C: 67/106[3]	IVTA: 0/106 C: 2/106	IVTA: 0/106 C: 0/106
Gobbur, 2014[37]	50/50	IVTA: 23.62 (3.43) C: 24.5 (3.98)	1 g 20 min before CS	Normal saline	IVTA: 360.9 (110.3)[2] C: 443.0 (88.55)[2]	IVTA: 6/50[7] C: 15/50[7]	NR	IVTA: 0/50 C: 0/50
Ramani, 2014[38]	60/60	IVTA: 24.9 (3.9) C: 24.4 (3.7)	1 g 10 min before CS	Normal saline	IVTA: 222.07 (97.02)[2] C: 274.5 (179.2)[2]	NR	IVTA: 2/60 C: 6/60	IVTA: 0/60 C: 0/60
Ahmed, 2015[39]	62/62	IVTA: 28.6 (5.9) C: 26.9 (5.2)	10 mg/kg 5 min before CS	Normal saline	IVTA: 391.0 (48.5)[2] C: 596.7 (38.02)[2]	NR	NR	IVTA: 0/62 C: 0/62
Maged, 2015[40]	100/100	IVTA: 24.9 (4.6) C: 25.3 (4.7)	1 g 20 min before CS	Normal saline	IVTA: 459.4 (75.4) C: 700.3 (143.9)	IVTA: 0/100[6] C: 6/100[6]	NR	IVTA: 0/100 C: 0/100
Lakshmi, 2016[41]	60/60	IVTA: 26.77 (2.81) C: 26.82 (2.8)	1 g 20 min before CS	No treatment	IVTA: 347.17 (180.6)[9] C: 517.72 (150.0)[9]	IVTA: 2/60[7] C: 36/60[7]	IVTA: 0/60 C: 0/60	IVTA: 0/60 C: 0/60
Sujata, 2016[42]	30/30	IVTA: 29.4 (4.16) C: 30.27 (4.31)	1 g 15 min before CS	Normal saline	IVTA: 432 (337-497)[5,10] C: 819 (663-1001)[5,10]	IVTA: 0/30[6] C: 7/30[6]	IVTA: 1/30 C: 4/30	IVTA: 0/30 C: 0/30

IVTA: intravenous tranexamic acid; C: controls; SD: standard deviation; min: minutes; CS: caesarean section; SAEs: severe adverse events; RBC: red blood cell transfusion; NR: not reported; PPH: post-partum haemorrhage; SA: spinal anaesthesia. [1]Mean (standard deviation); [2]measured from placental delivery to 2 hours post-partum; [3]defined as blood loss >400 mL; [4]measured from the end of cesarean section to 2 hours post-partum; [5]measured from the skin incision to 48 hours post-partum; [6]defined as blood loss >1,000 mL; [7]defined as blood loss >500 mL; [8]measured from placental delivery to 24 hours post-partum; [9]measured from placental delivery to the end of caesarean section; [10]median (interquartile range).

studies were unclear for random sequence generation and/or allocation concealment, while ten studies were at low risk of selection biases.

Blinding

There were nine studies reported as open label, and they were graded as high risk of performance bias (blinding of participants and personnel). Eight studies were reported as double blind[32-37,39,41,47], and one[45] as single blind; one of these studies[37] did not provide any information on the blinding procedures. Eleven studies were graded at unclear risk of detection bias

due to the fact that it did not provide information to permit judgement about "high" or "low" risk of bias related to the blinding of outcome assessors; one study[44] was graded at high risk of bias because it stated that the clinical care team was aware of the administered treatment.

Incomplete outcome data

One study[45] was judged at high risk of attrition bias because it reported only per protocol analysis. Two studies[31,44] were judged at unclear risk of bias. The remaining studies were judged at low risk of bias.

(A)

(B)

Figure 2 - Risk of bias graph and summary.
(A) Review authors' judgements about each risk of bias item presented as percentages across all included studies. (B) Review authors' judgements about each risk of bias item for each included study.

Selective reporting

Selective reporting was low in all included studies, and graded as "unclear" in one study[35] where some data were not presented in detail (e.g. some side effects) although the report states that there were no differences between groups.

Other potential sources of bias

We judged three studies at high risk of other source of bias: two because of imbalance at baseline[37,38], and one[36] because it did not mention PPH, enrolled anaemic women, and because there was a significant difference in the duration of surgery between groups.

Effects of interventions

The overall incidence of PPH was 71 cases on 395 treated patients (17.9%) and 172 cases on 391 control patients (43.9%). Using the average treatment effect from a random-effects model, the use of TA reduces significantly the episodes of PPH when compared with control group: five trials, 786 patients; RR 0.40, 95% CI: 0.24-0.65; p=0.0003 for overall effect; I^2=68% (Figure 3A). The overall incidence of severe PPH was 9 cases of 893 treated patients (1.0%) and 34 cases of 857 control patients (3.9%). Using the average treatment effect from a random-effects model, the use of TA significantly reduces the episodes of severe PPH when compared with control group: five trials, 1, 750 patients; RR 0.32, 95% CI: 0.12-0.84; p=0.02 for overall effect; I^2=19% (Figure 3B).

As far as secondary outcomes are concerned, using the average treatment effect from a fixed-effects model, the use of TA reduces the need of red blood cell transfusion compared to controls: ten trials, 1,873 patients; RR 0.30, 95% CI: 0.18-0.49; p=0.00001 for overall effect; I^2=0% (Figure 4). The overall incidence for blood transfusion was 16 cases of 943 treated patients (1.69%) and 55 cases of 930 control patients (5.91%). The NNT was calculated as 25.6.

Tranexamic acid reduces the amount (mL) of post-partum blood loss: mean difference −155.14 (95% CI: −192.69 to −157.58; p=0.00001 for overall effect) (Figure 5). The direction of the effect was consistent across studies, with a beneficial effect of TA, but there was a considerable heterogeneity (I^2=100%). The heterogeneity observed can be ascribed to different intervals of blood loss recorded (from placental delivery[30,33-35,38,42-44] or caesarean section[39] to two hours post-partum, from skin incision to 48 hours post-partum[32,47], from placental delivery to 24 hours post-partum[36], from placental delivery to the end of caesarean section[40,41,46]); to different populations of patients enrolled (e.g. several studies excluded anaemic women, but one study[36] included only anaemic women);

(A)

Study or Subgroup	TA Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
Gai 2014	22	91	35	89	26.2%	0.61 [0.39, 0.96]
Gobbur 2014	6	50	15	50	16.6%	0.40 [0.17, 0.95]
Lakshmi 2016	2	60	36	60	9.3%	0.06 [0.01, 0.22]
Xu 2013	8	88	19	86	18.5%	0.41 [0.19, 0.89]
Yehia 2014	33	106	67	106	29.3%	0.49 [0.36, 0.68]
Total (95% CI)		**395**		**391**	**100.0%**	**0.40 [0.24, 0.65]**
Total events	71		172			

Heterogeneity: Tau² = 0.19; Chi² = 12.56, df = 4 (P = 0.01); I² = 68%
Test for overall effect: Z = 3.64 (P = 0.0003)

(B)

Study or Subgroup	TA Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
Abdel-Aleem 2013	2	373	2	367	20.0%	0.98 [0.14, 6.95]
Gongorduk 2011	7	330	19	330	59.0%	0.37 [0.16, 0.86]
Goswami 2013	0	60	0	30		Not estimable
Maged 2015	0	100	6	100	10.4%	0.08 [0.00, 1.35]
Sujata 2016	0	30	7	30	10.6%	0.07 [0.00, 1.12]
Total (95% CI)		**893**		**857**	**100.0%**	**0.32 [0.12, 0.84]**
Total events	9		34			

Heterogeneity: Tau² = 0.22; Chi² = 3.71, df = 3 (P = 0.29); I² = 19%
Test for overall effect: Z = 2.32 (P = 0.02)

Figure 3 – Forest plot demonstrating effects of tranexamic acid (TA) on the incidence of (A) post-partum haemorrhage and (B) severe post-partum haemorrhage.
M-H: Mantel-Haenszel; CI: confidence interval.

Study or Subgroup	TA Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Ghosh 2014	0	70	3	70	6.0%	0.14 [0.01, 2.72]
Gongorduk 2011	2	330	7	330	12.1%	0.29 [0.06, 1.37]
Goswami 2013	0	60	2	30	5.7%	0.10 [0.01, 2.05]
Lakshmi 2016	0	60	0	60		Not estimable
Ramani 2014	2	60	6	60	10.4%	0.33 [0.07, 1.59]
Senturk 2013	0	101	0	122		Not estimable
Shahid 2013	3	38	12	36	21.3%	0.24 [0.07, 0.77]
Sujata 2016	1	30	4	30	6.9%	0.25 [0.03, 2.11]
Xu 2013	8	88	19	86	33.2%	0.41 [0.19, 0.89]
Yehia 2014	0	106	2	106	4.3%	0.20 [0.01, 4.12]
Total (95% CI)		**943**		**930**	**100.0%**	**0.30 [0.18, 0.49]**
Total events	16		55			

Heterogeneity: Chi² = 1.67, df = 7 (P = 0.98); I² = 0%
Test for overall effect: Z = 4.67 (P < 0.00001)

Figure 4 – Forest plot of the effect of tranexamic acid (TA) on red blood cell (RBC) transfusion need.
M-H: Mantel-Haenszel; CI: confidence interval.

Study or Subgroup	TA Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Abdel-Aleem 2013	241.61	126.02	373	510.66	144.52	367	5.9%	-269.05 [-288.60, -249.50]
Ahmed 2015	391	48.5	62	596.7	38.02	62	6.0%	-205.70 [-221.04, -190.36]
Gai 2014	359.29	152.02	91	439.36	191.48	89	5.4%	-80.07 [-130.65, -29.49]
Ghosh 2014	48.06	8.2	70	76.01	6.21	70	6.0%	-27.95 [-30.36, -25.54]
Gobbur 2014	360.9	110.3	50	443	88.55	50	5.6%	-82.10 [-121.31, -42.89]
Gongorduk 2011	499.9	206.4	330	600.7	215.7	330	5.8%	-100.80 [-133.01, -68.59]
Goswami 2013	376.83	31.96	60	527.17	88.67	30	5.8%	-150.34 [-183.08, -117.60]
Lakshmi 2016	347.17	108.6	60	517.72		150	6.1%	-170.55 [-217.41, -123.69]
Maged 2015	459.4	75.4	100	700.3	143.9	100	5.8%	-240.90 [-272.74, -209.06]
Movafegh 2011	262.5	39.6	50	404.7	94.4	50	5.8%	-142.20 [-170.57, -113.83]
Ramani 2014	222.07	97.02	60	274.5	179.2	60	5.6%	-52.43 [-103.99, -0.87]
Sekhavat 2009	28.02	5.53	45	37.12	8.97	45	6.0%	-9.10 [-12.18, -6.02]
Senturk 2013	272.05	143.23	101	346.87	189.49	122	5.6%	-74.82 [-118.53, -31.11]
Shahid 2013	356.44	143.2	38	710.22	216.72	36	4.6%	-353.78 [-437.95, -269.61]
Singh 2014	270.05	30.88	100	510.45	30.34	100	6.0%	-240.40 [-248.88, -231.92]
Sujata 2016	432	124.5	30	819	263.1	30	4.1%	-387.00 [-491.16, -282.84]
Xu 2013	379.2	160.1	88	441.7	189.5	86	5.4%	-62.50 [-114.68, -10.32]
Yehia 2014	369.5	198	106	606.8	193	106	5.4%	-237.30 [-289.94, -184.66]
Total (95% CI)			**1814**			**1793**	**100.0%**	**-155.14 [-192.69, -117.58]**

Heterogeneity: Tau² = 6105.15; Chi² = 4048.71, df = 17 (P < 0.00001); I² = 100%
Test for overall effect: Z = 8.10 (P < 0.00001)

Figure 5 – Forest plot of tranexamic acid (TA) on post-partum blood loss (mL).
CI: confidence interval.

to different dosage of TA used; and also to methods used to quantify the loss (e.g. weight of gauze pads, and/or sponges, mops, drapes; bloods in suction bottles; pre- and post-intervention haemoglobin values).

One study[34] reported severe side effects (deep vein thrombosis) in 2 of 88 TA recipients and in 2 of 86 controls (RR, 0.98, 95% CI: 0.14-6.78). The remaining 17 studies did not report severe adverse events, including thromboembolic events, in either group.

Based on GRADE assessment, all these comparisons were graded as moderate certainty evidence, and down-graded once due to inconsistency or to risk of biases (see Online Supplementary Content, Table SI).

Discussion

The antifibrinolytic agent TA is routinely used in cardiac, orthopaedic and oral surgeries to reduce perioperative blood loss[13-15]. Recent evidence from RCTs also indicate that TA usage results in a significant reduction of obstetric bleeding[20,48,49]. A recent randomised, placebo-controlled trial (WOMAN, WOrld Maternal ANtifibrinolytic) on 20,060 women with PPH found that TA reduces deaths due to bleeding (RR 0.81, 95% CI: 0.65-1.00; p=0.045) with no adverse effects, especially when given early after bleeding onset[50]. A Cochrane systematic review evaluating TA for preventing post-partum haemorrhage was recently published. After the analysis of 12 RCTs involving 3,285 women, the authors concluded that TA decreases postpartum blood loss and prevents PPH and blood transfusion requirements[51]. The results of our meta-analysis are in line with these observations and indicate that, in women undergoing caesarean delivery, the prophylactic use of TA significantly reduces the incidence of PPH, including severe PPH, total blood loss and transfusion requirements without increasing the risk of thromboembolic complications. The main strength of our study is that it represents a very large, up-to-date and comprehensive analysis which involved overall 4,557 women enrolled in 18 RCTs. In addition, most of the included studies are of high quality and with a low risk of bias according to the Cochrane risk of bias tools. Nevertheless, our systematic review has some limitations which are related to the different study designs of the RCTs evaluated that generate a substantial heterogeneity across studies. For instance, there were differences among the various RCTs in the definition of PPH (blood loss >400 or >500 mL) and post-partum blood loss assessment (2 hours, 24 hours or 48 hours post-partum). In particular, the abbreviated time for data collection may mean that total blood loss and the true incidence of PPH have been under-estimated. In addition, we were not able to detect the effect of TA on maternal death due to the lack of fatal events in the studies evaluated, which was probably related to the small size of the population of women enrolled. Larger RCTs on this clinical setting are, therefore, needed to assess this important outcome.

In summary, the results of our meta-analysis document the safety and efficacy of prophylactic administration of TA in reducing post-partum blood loss, PPH incidence and need for blood transfusion in women undergoing caesarean delivery. Therefore, given its efficacy in preventing one of the most common and serious complications of pregnancy, we recommend the use of TA in this clinical setting. The use of this drug in the framework of patient blood management (PBM) programmes[52-55] can play a key role as a strategy to save blood loss but, to be really beneficial in improving patient outcome and efficient for health systems, it should be part of an adequate management of perioperative anaemia[56,57]. In fact, the benefits of a PBM programme[58] are greater when it includes optimisation of patient's haemoglobin level[59-65]. This approach is very important also for the perinatal care of women, a setting where the management of anaemia and haematinic deficiencies should be obligatory both for clinicians and policymakers in charge of decision making processes aimed at up-dating clinical practice in health care[66].

Disclosure of conflicts of interest

References
1) Mehrabadi A, Hutcheon JA, Lee L, et al. Trends in postpartum hemorrhage from 2000 to 2009: a population-based study. BMC Pregnancy Childbirth 2012; **12**: 108.
2) Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; **384**: 980-1004.
3) Abdul-Kadir R, McLintock C, Ducloy AS, et al. Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion 2014; **54**: 1756-68.
4) Calvert C, Thomas SL, Ronsmans C, et al. Identifying regional variation in the prevalence of postpartum haemorrhage: a systematic review and meta-analysis. PLoS ONE 2012; **7**: e41114.
5) Mercier FJ, Van de Velde M. Major obstetric hemorrhage. Anesthesiol Clin 2008; **26**: 53-66.
6) Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric haemorrhage. BJOG Int J Obstet Gynaecol 2008; **115**: 1265-72.
7) Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; **30**: 270-382.
8) World Health Organization. *Managing complications in pregnancy and childbirth.* Geneva: WHO; 2007.
9) Istituto Superiore di Sanità. *Emorragia post-partum: come prevenirla, come curarla*. Linea Guida 26. Roma: ISS; 2016.

10) Pabinger I, Fries D, Schochl H, et al. Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. Wien Klin Wochenschr 2017; **129**: 303-16.

11) Cohen MJ, Christie SA. Coagulopathy of trauma. Crit Care Clin 2017; **33**: 101-18.

12) Franchini M, Mannucci PM. Adjunct agents for bleeding. Curr Opin Hematol 2014; **21**: 503-8.

13) Franchini M, Mengoli C, Marietta M, et al. Safety of intravenous tranexamic acid in patients undergoing major orthopedic surgery: a meta-analysis of randomized controlled trial. Blood Transfus 2018; **16**: 36-43.

14) Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2015; **5**: CD004896.

15) Gerstein NS, Brierley JK, Windsor J, et al. Antifibrinolytic agents in cardiac and noncardiac surgery: a comprehensive overview and update. J Cardiothorac Vasc Anesth 2017; **31**: 2183-205.

16) World Health Organization. *WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage*. Geneva: WHO; 2017.

17) Li C, Gong Y, Dong L, et al. Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage? A systematic review and meta-analysis. Medicine (Baltimore) 2017; **96**: e5653.

18) Sentilhes L, Lasocki S, Ducloy-Bouthors AS, et al. Tranexamic acid for the prevention and treatment of postpartum hemorrhage. Br J Anaesth 2015; **114**: 576-87.

19) Simonazzi G, Bisulli M, Saccone G, et al. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand 2016; **95**: 28-37.

20) Ker K, Shakur H, Roberts I. Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomized controlled trials. BJOG 2016; **123**: 1745-52.

21) Alam A, Choi S. Prophylactic use of tranexamic acid for postpartum bleeding outcomes: a systematic review and meta-analysis of randomized controlled trials. Transfus Med Rev 2015; **29**: 231-41.

22) Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; **62**: 1006-12.

23) Gungorduk K, Asıcıoğlu O, Yıldırım G, et al. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Am J Perinatol 2013; **30**: 407-13.

24) Mirghafourvand M, Mohammed-Alizadeh S, Abbasalizadeh F, Shrdel M. The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum hemorrhage. A double-blind randomized controlled trial. Aust NZJ Obstet Gynaecol 2015; **55**: 53-8.

25) Higgins JP, Green S, editors: Cochrane Handbook for Systematic Reviews of Interventions - Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available at: http://www.cochranehandbook.org. Accessed on 31/01/2018.

26) Guyatt GH, Oxman AD, Kunz R, et al. What is 'quality of evidence' and why is it important to clinicians? BMJ 2008; **336**: 995-8.

27) Schünemann HJ, Oxman AD, Higgins JP, et al. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at: www.handbook.cochrane.org. Accessed on 31/01/2018.

28) Schünemann HJ, Oxman AD, Higgins JP, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at: www.handbook.cochrane.org. Accessed on 31/01/2018.

29) DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; **7**: 177-88.

30) Gai MY, Wu LF, Su QF, et al. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Euro J Obstet Gynecol Reprod Biol 2004; **112**: 154-7.

31) Sekhavat L, Tabatabaii A, Dalili M, et al. Efficacy of tranexamic acid in reducing blood loss after cesarean section. J Matern Fetal Neonatal Med 2009; **22**: 72-5.

32) Gungorduk K, Asıcıoğlu O, Yıldırım G, et al. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011; **28**: 233-40.

33) Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet 2011; **115**: 224-6.

34) Xu J, Gao W, Ju Y. Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section: a double-blind randomization trial. Arch Gynecol Obstet 2013; **287**: 463-8.

35) Shahid A, Khan K. Tranexamic acid in decreasing blood loss during and after caesarean section. J Coll Physicians Surg Pak 2013; **23**: 459-62.

36) Goswami U, Sarangi S, Gupta S, et al. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: A double-blind randomized case control prospective trial. Saudi J Anaesth 2013; **7**: 427-31.

37) Sentürk MB, Cakmak Y, Yildiz G, Yildiz P. Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial. Arch Gynecol Obstet 2013; **287**: 641-5.

38) Abdel-Aleem H, Alhusaini TK, Abdel-Aleem MA, et al. Effectiveness of tranexamic acid on blood loss in patients undergoing elective cesarean section: randomized clinical trial. J Matern Fetal Neonatal Med 2013; **26**: 1705-9.

39) Ghosh A, Chaudhuri P, Muhuri B. Efficacy of intravenous tranexamic acid before cesarean section in preventing post-partum hemorrhage-a prospective randomized double blind placebo controlled study. Int J Bio Med Res 2014; **5**: 4461-4.

40) Singh T, Burute SB, Deshpande HG, et al. Efficacy of tranexamic acid in decreasing blood loss during and after caesarean section: a randomized case control prospective study. J Evolut Med Dent Sci 2014; **3**: 2780-8.

41) Yehia AH, Koleib MH, Abdelazim IA, et al. Tranexamic acid reduces blood loss during and after cesarean section: a double blinded, randomized, controlled trial. Asian Pac J Reprod 2014; **3**: 53-6.

42) Gobbur V, Shiragur S, Jhanwar U, et al. Efficacy of tranexamic acid in reducing blood loss during lower segment caesarean section. Int J Reprod Contracept Obstet Gynecol 2014; **3**: 414-7.

43) Ramani B, Nayak L. Intravenous 1 gram tranexamic acid for prevention of blood loss and blood transfusion during caesarean section: a randomized case control study. Int J Reprod Contracept Obstet Gynecol 2014; **3**: 366-9.

44) Ahmed MR, Sayed Ahmed WA, Madny EH, et al. Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery. J Matern Fetal Neonatal Med 2015; **28**: 1014-8.

45) Maged AM, Helal OM, Elsherbini MM, et al. A randomized placebocontrolled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery. Int J Gynaecol Obstet 2015; **131**: 265-8.

46) Lakshmi SJD, Abraham R. Role of prophylactic tranexamic acid in reducing bloodloss during elective cesarean section: a randomized controlled study. J Clin Diagn Res 2016; **10**: QC17-21.

47) Sujata N, Tobin R, Kaur R, et al. Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. Int J Gynaecol Obstet 2016; **133**: 312-5.

48) Ducloy-Bouthors AS, Jude B, et al.; EXADELI Study Group, Susen S. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011; **15**: R117.

49) Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 2018; **391**: 125-32.

50) WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; **389**: 2105-16.

51) Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2015; **6:** CD007872.

52) Vaglio S, Gentili S, Marano G, et al. The Italian Regulatory Guidelines for the implementation of Patient Blood Management. Blood Transfus 2017; **15**: 325-8.

53) Vaglio S, Prisco D, Biancofiore G, et al. Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus 2016; **14**: 23-65.

54) Guerra R, Velati C, Liumbruno GM, Grazzini G. Patient Blood Management in Italy. Blood Transfus 2016; **14**: 1-2.

55) Franchini M, Muñoz M. Towards the implementation of patient blood management across Europe. Blood Transfus 2017; **15:** 292-3.

56) Muñoz M, Gómez-Ramírez S, Kozek-Langeneker S, et al. 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. Br J Anaesth 2015; **115**: 15-24.

57) Muñoz M, Gómez-Ramírez S, Campos A, et al. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus 2015; **13**: 370-9.

58) Liumbruno GM, Vaglio S, Grazzini G, et al. Patient blood management: a fresh look at a fresh approach to blood transfusion. Minerva Anestesiol 2015; **81**: 1127-37.

59) Liumbruno GM, Vaglio S, Biancofiore G, et al. Transfusion thresholds and beyond. Blood Transfus 2016; **14**: 123-5.

60) Franchini M, Marano G, Mengoli C, et al. Red blood cell transfusion policy: a critical literature review. Blood Transfus 2017; **15**: 307-17.

61) Girelli D, Marchi G, Busti F. Iron replacement therapy: entering the new era without misconceptions, but more research is needed. Blood Transfus 2017; **15**: 379-81.

62) Muñoz M, Gómez-Ramírez S, Besser M, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017; **15**: 422-37.

63) Muñoz M, Gómez-Ramírez S, Liumbruno GM. Peri-operative anaemia management in major orthopaedic surgery: the need to find a pathway. Blood Transfus 2017; **15**: 289-91.

64) Bisbe E, Basora M, Colomina MJ; Spanish Best Practice in Peri-operative Anaemia Optimisation Panel. Peri-operative treatment of anaemia in major orthopaedic surgery: a practical approach from Spain. Blood Transfus 2017; **15**: 296-306.

65) Quintana-Díaz M, Muñoz-Romo R, Gómez-Ramírez S, et al. A fast-track anaemia clinic in the Emergency Department: cost-analysis of intravenous iron administration for treating iron-deficiency anaemia. Blood Transfus 2017; **15**: 438-46.

66) Muñoz M, Peña-Rosas JP, Robinson S, et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfus Med 2018; **28**: 22-39.